Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
11
CADL Quote, Financials, Valuation and Earnings
Last price:
$5.25
Seasonality move
:
-19.31%
Day range:
$5.20 - $5.54
52-week range:
$4.25 - $9.13
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1,949.18x
P/B ratio:
3.60x
Volume:
2.1M
Avg. volume:
1.1M
1-year change:
-38.95%
Market cap:
$288.2M
Revenue:
--
EPS (TTM):
-$0.56
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CADL
Candel Therapeutics, Inc.
|
-- | -$0.24 | -- | -40.61% | $18.63 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$304.5M | $0.11 | 15.84% | -39.29% | $31.80 |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$1.3B | $2.18 | 89.86% | -58.59% | $457.00 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$952.5M | $1.10 | 4.94% | 9.76% | $88.17 |
|
IMNN
Imunon, Inc.
|
-- | -$0.74 | -- | -269.06% | $21.50 |
|
SVRA
Savara, Inc.
|
-- | -$0.12 | -- | -2.6% | $10.81 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CADL
Candel Therapeutics, Inc.
|
$5.25 | $18.63 | $288.2M | -- | $0.00 | 0% | 1,949.18x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$24.56 | $31.80 | $4.2B | 10.73x | $0.00 | 0% | 3.89x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$332.92 | $457.00 | $44.2B | 147.50x | $0.00 | 0% | 11.97x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$61.73 | $88.17 | $11.9B | 34.65x | $0.00 | 0% | 3.70x |
|
IMNN
Imunon, Inc.
|
$3.25 | $21.50 | $6.9M | -- | $0.00 | 0% | 16.43x |
|
SVRA
Savara, Inc.
|
$6.02 | $10.81 | $1.2B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CADL
Candel Therapeutics, Inc.
|
8.25% | 2.080 | 2.57% | 7.96x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
4.08% | 2.900 | 1.15% | 3.40x |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
79% | 1.064 | 5.64% | 2.51x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
8.93% | -0.896 | 5.23% | 3.25x |
|
IMNN
Imunon, Inc.
|
21.26% | 5.236 | 10.13% | 1.25x |
|
SVRA
Savara, Inc.
|
24.02% | -1.971 | 4.83% | 7.42x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CADL
Candel Therapeutics, Inc.
|
-$195K | -$13.2M | -32.33% | -38.43% | -- | -$10.4M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257.8M | $17.4M | 41.28% | 43.78% | 6.12% | -$52.7M |
|
ALNY
Alnylam Pharmaceuticals, Inc.
|
$829.3M | $131.7M | 10.18% | 107.73% | 12.01% | $140.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$598.9M | $79.4M | 5.34% | 5.89% | 9.08% | $56.6M |
|
IMNN
Imunon, Inc.
|
-$167K | -$3.5M | -282.76% | -365% | -- | -$4.4M |
|
SVRA
Savara, Inc.
|
-$76K | -$30.3M | -65.99% | -78.83% | -- | -$22.5M |
Candel Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns CADL or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of -- compared to Candel Therapeutics, Inc.'s net margin of 96.33%. Candel Therapeutics, Inc.'s return on equity of -38.43% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 43.78%.
Company Gross Margin Earnings Per Share Invested Capital CADLCandel Therapeutics, Inc.-- -$0.21 $87.3M ACADACADIA Pharmaceuticals, Inc.90.77% $1.60 $1.3B -
What do Analysts Say About CADL or ACAD?
Candel Therapeutics, Inc. has a consensus price target of $18.63, signalling upside risk potential of 254.76%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $31.80 which suggests that it could grow by 29.48%. Given that Candel Therapeutics, Inc. has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Candel Therapeutics, Inc. is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CADLCandel Therapeutics, Inc.7 1 0 ACADACADIA Pharmaceuticals, Inc.11 5 1 -
Is CADL or ACAD More Risky?
Candel Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.660, suggesting its less volatile than the S&P 500 by 33.951%.
-
Which is a Better Dividend Stock CADL or ACAD?
Candel Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Candel Therapeutics, Inc. pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CADL or ACAD?
Candel Therapeutics, Inc. quarterly revenues are --, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $284M. Candel Therapeutics, Inc.'s net income of -$11.3M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $273.6M. Notably, Candel Therapeutics, Inc.'s price-to-earnings ratio is -- while ACADIA Pharmaceuticals, Inc.'s PE ratio is 10.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics, Inc. is 1,949.18x versus 3.89x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CADLCandel Therapeutics, Inc.1,949.18x -- -- -$11.3M ACADACADIA Pharmaceuticals, Inc.3.89x 10.73x $284M $273.6M
-
Which has Higher Returns CADL or ALNY?
Alnylam Pharmaceuticals, Inc. has a net margin of -- compared to Candel Therapeutics, Inc.'s net margin of 16.99%. Candel Therapeutics, Inc.'s return on equity of -38.43% beat Alnylam Pharmaceuticals, Inc.'s return on equity of 107.73%.
Company Gross Margin Earnings Per Share Invested Capital CADLCandel Therapeutics, Inc.-- -$0.21 $87.3M ALNYAlnylam Pharmaceuticals, Inc.75.6% $1.37 $3.8B -
What do Analysts Say About CADL or ALNY?
Candel Therapeutics, Inc. has a consensus price target of $18.63, signalling upside risk potential of 254.76%. On the other hand Alnylam Pharmaceuticals, Inc. has an analysts' consensus of $457.00 which suggests that it could grow by 37.27%. Given that Candel Therapeutics, Inc. has higher upside potential than Alnylam Pharmaceuticals, Inc., analysts believe Candel Therapeutics, Inc. is more attractive than Alnylam Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CADLCandel Therapeutics, Inc.7 1 0 ALNYAlnylam Pharmaceuticals, Inc.15 7 0 -
Is CADL or ALNY More Risky?
Candel Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Alnylam Pharmaceuticals, Inc. has a beta of 0.350, suggesting its less volatile than the S&P 500 by 65.025%.
-
Which is a Better Dividend Stock CADL or ALNY?
Candel Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Alnylam Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Candel Therapeutics, Inc. pays -- of its earnings as a dividend. Alnylam Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CADL or ALNY?
Candel Therapeutics, Inc. quarterly revenues are --, which are smaller than Alnylam Pharmaceuticals, Inc. quarterly revenues of $1.1B. Candel Therapeutics, Inc.'s net income of -$11.3M is lower than Alnylam Pharmaceuticals, Inc.'s net income of $186.4M. Notably, Candel Therapeutics, Inc.'s price-to-earnings ratio is -- while Alnylam Pharmaceuticals, Inc.'s PE ratio is 147.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics, Inc. is 1,949.18x versus 11.97x for Alnylam Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CADLCandel Therapeutics, Inc.1,949.18x -- -- -$11.3M ALNYAlnylam Pharmaceuticals, Inc.11.97x 147.50x $1.1B $186.4M
-
Which has Higher Returns CADL or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -- compared to Candel Therapeutics, Inc.'s net margin of -5.33%. Candel Therapeutics, Inc.'s return on equity of -38.43% beat BioMarin Pharmaceutical, Inc.'s return on equity of 5.89%.
Company Gross Margin Earnings Per Share Invested Capital CADLCandel Therapeutics, Inc.-- -$0.21 $87.3M BMRNBioMarin Pharmaceutical, Inc.68.48% -$0.24 $6.7B -
What do Analysts Say About CADL or BMRN?
Candel Therapeutics, Inc. has a consensus price target of $18.63, signalling upside risk potential of 254.76%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $88.17 which suggests that it could grow by 42.84%. Given that Candel Therapeutics, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Candel Therapeutics, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CADLCandel Therapeutics, Inc.7 1 0 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is CADL or BMRN More Risky?
Candel Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock CADL or BMRN?
Candel Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Candel Therapeutics, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CADL or BMRN?
Candel Therapeutics, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $874.6M. Candel Therapeutics, Inc.'s net income of -$11.3M is higher than BioMarin Pharmaceutical, Inc.'s net income of -$46.6M. Notably, Candel Therapeutics, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 34.65x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics, Inc. is 1,949.18x versus 3.70x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CADLCandel Therapeutics, Inc.1,949.18x -- -- -$11.3M BMRNBioMarin Pharmaceutical, Inc.3.70x 34.65x $874.6M -$46.6M
-
Which has Higher Returns CADL or IMNN?
Imunon, Inc. has a net margin of -- compared to Candel Therapeutics, Inc.'s net margin of --. Candel Therapeutics, Inc.'s return on equity of -38.43% beat Imunon, Inc.'s return on equity of -365%.
Company Gross Margin Earnings Per Share Invested Capital CADLCandel Therapeutics, Inc.-- -$0.21 $87.3M IMNNImunon, Inc.-- -$1.16 $5.2M -
What do Analysts Say About CADL or IMNN?
Candel Therapeutics, Inc. has a consensus price target of $18.63, signalling upside risk potential of 254.76%. On the other hand Imunon, Inc. has an analysts' consensus of $21.50 which suggests that it could grow by 561.54%. Given that Imunon, Inc. has higher upside potential than Candel Therapeutics, Inc., analysts believe Imunon, Inc. is more attractive than Candel Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CADLCandel Therapeutics, Inc.7 1 0 IMNNImunon, Inc.3 1 0 -
Is CADL or IMNN More Risky?
Candel Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Imunon, Inc. has a beta of 2.135, suggesting its more volatile than the S&P 500 by 113.504%.
-
Which is a Better Dividend Stock CADL or IMNN?
Candel Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Imunon, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Candel Therapeutics, Inc. pays -- of its earnings as a dividend. Imunon, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CADL or IMNN?
Candel Therapeutics, Inc. quarterly revenues are --, which are smaller than Imunon, Inc. quarterly revenues of --. Candel Therapeutics, Inc.'s net income of -$11.3M is lower than Imunon, Inc.'s net income of -$3.4M. Notably, Candel Therapeutics, Inc.'s price-to-earnings ratio is -- while Imunon, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics, Inc. is 1,949.18x versus 16.43x for Imunon, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CADLCandel Therapeutics, Inc.1,949.18x -- -- -$11.3M IMNNImunon, Inc.16.43x -- -- -$3.4M
-
Which has Higher Returns CADL or SVRA?
Savara, Inc. has a net margin of -- compared to Candel Therapeutics, Inc.'s net margin of --. Candel Therapeutics, Inc.'s return on equity of -38.43% beat Savara, Inc.'s return on equity of -78.83%.
Company Gross Margin Earnings Per Share Invested Capital CADLCandel Therapeutics, Inc.-- -$0.21 $87.3M SVRASavara, Inc.-- -$0.14 $124.2M -
What do Analysts Say About CADL or SVRA?
Candel Therapeutics, Inc. has a consensus price target of $18.63, signalling upside risk potential of 254.76%. On the other hand Savara, Inc. has an analysts' consensus of $10.81 which suggests that it could grow by 79.61%. Given that Candel Therapeutics, Inc. has higher upside potential than Savara, Inc., analysts believe Candel Therapeutics, Inc. is more attractive than Savara, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CADLCandel Therapeutics, Inc.7 1 0 SVRASavara, Inc.6 0 0 -
Is CADL or SVRA More Risky?
Candel Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Savara, Inc. has a beta of 0.336, suggesting its less volatile than the S&P 500 by 66.415%.
-
Which is a Better Dividend Stock CADL or SVRA?
Candel Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Savara, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Candel Therapeutics, Inc. pays -- of its earnings as a dividend. Savara, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CADL or SVRA?
Candel Therapeutics, Inc. quarterly revenues are --, which are smaller than Savara, Inc. quarterly revenues of --. Candel Therapeutics, Inc.'s net income of -$11.3M is higher than Savara, Inc.'s net income of -$29.6M. Notably, Candel Therapeutics, Inc.'s price-to-earnings ratio is -- while Savara, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Candel Therapeutics, Inc. is 1,949.18x versus -- for Savara, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CADLCandel Therapeutics, Inc.1,949.18x -- -- -$11.3M SVRASavara, Inc.-- -- -- -$29.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
54
AAOI alert for Feb 28
Applied Optoelectronics, Inc. [AAOI] is up 56.96% over the past day.
Buy
90
BNAI alert for Feb 28
Brand Engagement Network, Inc. [BNAI] is up 36.02% over the past day.
Sell
36
WLDN alert for Feb 28
Willdan Group, Inc. [WLDN] is down 25.56% over the past day.
